Loading...
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
OBJECTIVES: To compare patient-reported outcomes (PROs) in methotrexate (MTX)-naive patients (defined as no prior treatment or ≤3 doses) receiving tofacitinib versus MTX. METHODS: In the 24-month, phase III, randomised, controlled, ORAL Start trial (NCT01039688), patients were randomised 2:2:1 to re...
Na minha lista:
| Udgivet i: | RMD Open |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5051508/ https://ncbi.nlm.nih.gov/pubmed/27752357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000308 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|